Telix Pharmaceuticals (TLPPF) Stock Forecast & Price Target

Compare

155 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TLPPF Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Telix

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TLPPF Stock 12 Month Forecast

Average Price Target

$17.63

▲(128.36% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $17.63 with a high forecast of $22.82 and a low forecast of $11.41. The average price target represents a 128.36% change from the last price of $7.72.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","23":"$23","10.25":"$10.25","14.5":"$14.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.81553,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.629310785714285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.407765,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.25,14.5,18.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.58,8.751963846153846,9.923927692307693,11.095891538461538,12.267855384615384,13.43981923076923,14.611783076923075,15.783746923076922,16.95571076923077,18.127674615384613,19.299638461538457,20.471602307692308,21.64356615384615,{"y":22.81553,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.58,8.353023906593407,9.126047813186814,9.89907171978022,10.672095626373626,11.445119532967034,12.21814343956044,12.991167346153846,13.764191252747253,14.53721515934066,15.310239065934066,16.08326297252747,16.85628687912088,{"y":17.629310785714285,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.58,7.874443461538462,8.168886923076924,8.463330384615384,8.757773846153846,9.052217307692308,9.34666076923077,9.64110423076923,9.935547692307692,10.229991153846154,10.524434615384616,10.818878076923077,11.113321538461538,{"y":11.407765,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.58,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.82

Average Price Target$17.63

Lowest Price Target$11.41

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Shane Storey

Canaccord Genuity

$19.12

Buy

147.73%

Upside

Reiterated

01/20/26

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Spyre Therapeutics (NASDAQ: SYRE)

David Dai

UBS

$20.8

Buy

169.46%

Upside

Reiterated

01/19/26

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Agilon Health (NYSE: AGL)

Craig Wong-Pan

RBC Capital

$11.41

Buy

47.77%

Upside

Upgraded

01/18/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Telix Pharmaceuticals (Other OTC: TLPPF)

Laura Sutcliffe

Citi

$22.82

Buy

195.54%

Upside

Reiterated

01/16/26

Analysts' Top Healthcare Picks: Telix Pharmaceuticals (TLPPF), Mereo Biopharma Group Plc (MREO)

Tara Bancroft

TD Cowen

$23.49→$16.78

Buy

117.31%

Upside

Reiterated

12/30/25

TD Cowen Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

David Bailey

Morgan Stanley

$17.04

Buy

120.78%

Upside

Reiterated

11/20/25

Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley

John Hester

Bell Potter

$15.43

Buy

99.92%

Upside

Reiterated

10/22/25

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

$18.88→$18.83

Buy

143.91%

Upside

Reiterated

10/16/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$15.17

Buy

96.45%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

David Stanton

Jefferies

$17.92→$18.19

Buy

135.56%

Upside

Reiterated

10/14/25

Jefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Andrew Paine

CLSA

$16.27

Buy

110.79%

Upside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

David Low

J.P. Morgan

$17.61→$11.07

Hold

43.42%

Upside

Downgraded

08/31/25

J.P. Morgan downgrades Telix Pharmaceuticals (TLPPF) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Shane Storey

Canaccord Genuity

$19.12

Buy

147.73%

Upside

Reiterated

01/20/26

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Spyre Therapeutics (NASDAQ: SYRE)

David Dai

UBS

$20.8

Buy

169.46%

Upside

Reiterated

01/19/26

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Agilon Health (NYSE: AGL)

Craig Wong-Pan

RBC Capital

$11.41

Buy

47.77%

Upside

Upgraded

01/18/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Telix Pharmaceuticals (Other OTC: TLPPF)

Laura Sutcliffe

Citi

$22.82

Buy

195.54%

Upside

Reiterated

01/16/26

Analysts' Top Healthcare Picks: Telix Pharmaceuticals (TLPPF), Mereo Biopharma Group Plc (MREO)

Tara Bancroft

TD Cowen

$23.49→$16.78

Buy

117.31%

Upside

Reiterated

12/30/25

TD Cowen Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

David Bailey

Morgan Stanley

$17.04

Buy

120.78%

Upside

Reiterated

11/20/25

Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley

John Hester

Bell Potter

$15.43

Buy

99.92%

Upside

Reiterated

10/22/25

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

$18.88→$18.83

Buy

143.91%

Upside

Reiterated

10/16/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$15.17

Buy

96.45%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

David Stanton

Jefferies

$17.92→$18.19

Buy

135.56%

Upside

Reiterated

10/14/25

Jefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Andrew Paine

CLSA

$16.27

Buy

110.79%

Upside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

David Low

J.P. Morgan

$17.61→$11.07

Hold

43.42%

Upside

Downgraded

08/31/25

J.P. Morgan downgrades Telix Pharmaceuticals (TLPPF) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

3 Months

xxx

Success Rate

12/16 ratings generated profit

Average Return

+25.22%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +25.22% per trade.

1 Year

Steven WheenJarden

Success Rate

16/22 ratings generated profit

Average Return

+48.30%

reiterated a buy rating 3 months ago

Copying Steven Wheen's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +48.30% per trade.

2 Years

xxx

Success Rate

13/22 ratings generated profit

Average Return

+91.51%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 59.09% of your transactions generating a profit, with an average return of +91.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLPPF Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TLPPF has received 12 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TLPPF average Analyst price target in the past 3 months is 17.63.

Each month's total comprises the sum of three months' worth of ratings.

TLPPF Financial Forecast

TLPPF Earnings Forecast

Currently, no earnings data available.

TLPPF Sales Forecast

Currently, no sales data available.

TLPPF Stock Forecast FAQ

What is TLPPF’s average 12-month price target, according to analysts?

Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 17.63.

What is TLPPF’s upside potential, based on the analysts’ average price target?

Telix Pharmaceuticals Ltd. has 128.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TLPPF a Buy, Sell or Hold?

Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Telix Pharmaceuticals Ltd.’s price target?

The average price target for Telix Pharmaceuticals Ltd. is 17.63. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.82 ,the lowest forecast is $11.41. The average price target represents 128.36% Increase from the current price of $7.72.

What do analysts say about Telix Pharmaceuticals Ltd.?

Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of TLPPF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Telix Pharmaceuticals (TLPPF) Stock Forecast & Price Target

TLPPF Analyst Ratings

TLPPF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Telix Pharmaceuticals

TLPPF Analyst Recommendation Trends

TLPPF Financial Forecast

TLPPF Earnings Forecast

TLPPF Sales Forecast

TLPPF Stock Forecast FAQ

Detailed List of Analyst Forecasts